rethinkTHC Search
Menu
Study breakdown

Cannabis might help pediatric IBD symptoms but evidence is far too limited to recommend use

ReviewPreliminary evidence
The takeaway

While cannabis shows potential anti-inflammatory effects relevant to inflammatory bowel disease, the evidence in pediatric IBD is insufficient to support clinical use, with calls for more targeted research on safety and efficacy in children.

Parents of children with IBD, pediatric gastroenterologists, and anyone interested in cannabis for inflammatory conditions in children.

Pediatric IBD is rising, but cannabis cannot yet be recommended for children

What the researchers found

Cannabis may relieve IBD symptoms and improve quality of life in individual patients. The endocannabinoid system plays a role in gastrointestinal tract function with potential anti-inflammatory effects. However, no adequate pediatric evidence exists to recommend cannabis or cannabinoids for IBD in children.

Why it matters

Pediatric IBD is rising, and parents are increasingly asking about cannabis options. This review provides clinicians with a framework for discussing why cannabis cannot yet be recommended for children with IBD despite adult-oriented enthusiasm.

The numbers in context

Rising incidence of pediatric IBD onset. Current treatment relies on immunomodulatory therapy. Cannabis and purified ingredients show potential anti-inflammatory effects. No adequate pediatric safety or efficacy data exist.

How the study worked

Narrative review of recent literature on cannabis use in IBD with a focus on pediatric patients, including background on the endocannabinoid system in the gastrointestinal tract and discussion of various cannabis forms and purified ingredients.

What this study cannot tell us

Narrative review without systematic methodology. Limited primary research on cannabis in pediatric IBD. Draws mostly from adult data and extrapolation. Does not quantify the strength of anti-inflammatory effects.

How to read the evidence

Preliminary: narrative review acknowledging a fundamental lack of pediatric-specific evidence.

When this study was published

Published in 2019.

The bigger picture

The gap between adult interest in cannabis for IBD and pediatric evidence is particularly stark. Children metabolize drugs differently, have developing immune systems, and face different risk-benefit calculations than adults, making extrapolation from adult data inappropriate.

Questions still open

  • What specific cannabinoids might be safest and most effective for pediatric IBD? Could topical or rectal administration minimize systemic exposure in children? What outcomes should pediatric clinical trials prioritize?

Common questions

Can cannabis help children with IBD?
It might, based on anti-inflammatory mechanisms and some adult patient reports. However, there is not enough evidence to recommend cannabis for pediatric IBD. The authors call for targeted pediatric research before any clinical use.
Why can't we just use adult IBD data for children?
Children metabolize drugs differently, have developing immune systems, and face different risks. Extrapolating adult cannabis data to children is inappropriate without pediatric-specific studies on safety and efficacy.

Read the original research

Cannabis, a potential treatment option in pediatric IBD? Still a long way to go.

Expert review of clinical pharmacology, 12(4), 355-361

Citation

Halbmeijer, Nienke; Groeneweg, Michael; De Ridder, Lissy. (2019). Cannabis, a potential treatment option in pediatric IBD? Still a long way to go.. Expert review of clinical pharmacology, 12(4), 355-361. https://doi.org/10.1080/17512433.2019.1582330

Explore the wider topic